Related Experiment Video
Updated: Oct 31, 2025

Studying Chronic Exposure of Mice to Ultraviolet B Radiation
Published on: August 19, 2025
Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor
On B Chan1, John C Su2,3, Anousha Yazdabadi1,2
1Department of Dermatology, Eastern Health, Monash University, Victoria, Australia.
Abstract:
Ribociclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is used in combination with an aromatase inhibitor in the first-line setting for advanced or metastatic hormone receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We report two cases of drug-induced vitiligo-like depigmentation (DI-VLD) associated with ribociclib. The awareness of this side effect is important given the increasing use of this drug and others with a similar mechanism of action.
Related Concept Videos
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Dipeptidyl Peptidase 4 Inhibitors
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Drugs that Destabilize Microtubules
Positive Regulator Molecules

